Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOS1 | Q07889 | 2/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | TDO2 | P48775 | 1/20 | 0.35 |
| ▸ | IDO2 | Q6ZQW0 | 1/20 | 0.35 |
| ▸ | MGLL | Q99685 | 1/20 | 0.35 |
| ▸ | DHFR | P00374 | 1/20 | 0.35 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.33 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4075958 | 0.91 | KDM4E (0.38) | SOS1IDO1TDO2IDO2FGFR1 | |
| SCHEMBL13881922 | 0.88 | FGFR1 (0.38) | IDO1TDO2IDO2FGFR1MAPT | |
| SCHEMBL4137225 | 0.86 | F10 (0.41) | IDO1TDO2IDO2SCN9AMAPT | |
| SCHEMBL3966950 | 0.86 | IDO1 (0.35) | IDO1TDO2IDO2FGFR1MAPT | |
| SCHEMBL3970595 | 0.86 | IDO1 (0.36) | SOS1IDO1TDO2IDO2MAPT | |
| SCHEMBL4143703 | 0.84 | FGFR1 (0.39) | IDO1TDO2IDO2FGFR1MAPT | |
| SCHEMBL4139178 | 0.84 | APP (0.41) | IDO1TDO2IDO2FGFR1PIK3CA | |
| SCHEMBL4071227 | 0.83 | IDO1 (0.40) | IDO1TDO2IDO2FGFR1PIK3CA | |
| SCHEMBL13881532 | 0.83 | IDO1 (0.38) | IDO1TDO2IDO2FGFR1PIK3CA | |
| SCHEMBL3971049 | 0.83 | FGFR1 (0.41) | IDO1TDO2IDO2FGFR1PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009041904-A1 | QUINOLINE COMPOUNDS HAVING AN ACTIVITY AGAINST THE GABAB RECEPTOR | ASTRAZENECA AB (SE) | 2009-04-02 | — | — | WO | claimed |
| US-20090088441-A1 | Quinoline Compounds | ASTRAZENECA AB (SE) | 2009-04-02 | — | — | US | claimed |
| US-20090088441-A1 | Quinoline Compounds | ASTRAZENECA AB (SE) | 2009-04-02 | — | — | US | disclosed |
| US-20090088441-A1 | Quinoline Compounds | ASTRAZENECA AB (SE) | 2009-04-02 | — | — | US | disclosed |
| US-20090088441-A1 | Quinoline Compounds | ASTRAZENECA AB (SE) | 2009-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088441-A1 | Quinoline Compounds | GABRB1, HRH2, GABRA5 | SOS1 2662/4885IDO1 996/4885TDO2 2448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.